Full Press Release Details
Precigen Announces Departure of Chief Financial
- Commences search for new CFO -
Germantown, Maryland, March 30, 2021 -
Precigen, Inc., a biopharmaceutical company specializing in the development of innovative gene and cell therapies to improve the lives
of patients, today announced that by mutual agreement Rick Sterling is stepping down from his position as Chief Financial Officer effective
April 2, 2021. Precigen has commenced an executive search for a successor with the qualifications to contribute to Precigen's accelerating
growth from a clinical stage company to a commercial organization.
"We thank Rick for his dedication and greatly
appreciate his contributions to our team throughout his tenure at Precigen and Intrexon and wish him well in his future endeavors,"
said Helen Sabzevari, PhD, President and Chief Executive Officer of Precigen. "We have made significant progress across our pipeline
programs and are preparing for the next phase of our growth, emphasizing commercial readiness for our lead products. We are seeking to
hire a new CFO who will be able to position our company for commercial success and ensure that we maintain our rapid growth and accelerated
Precigen: Advancing Medicine with Precision
Precigen (Nasdaq: PGEN) is a dedicated discovery
and clinical stage biopharmaceutical company advancing the next generation of gene and cell therapies using precision technology to target
the most urgent and intractable diseases in our core therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases.
Our technologies enable us to find innovative solutions for affordable biotherapeutics in a controlled manner. Precigen operates as an
innovation engine progressing a preclinical and clinical pipeline of well-differentiated unique therapies toward clinical proof-of-concept
and commercialization. For more information about Precigen, visit www.precigen.com or follow us
on Twitter @Precigen and LinkedIn.
Precigen and Advancing
Medicine with Precision are trademarks of Precigen and/or its affiliates. Other names may be trademarks of their respective owners.
Cautionary Statement Regarding Forward-Looking
Some of the statements made in this press release
are forward-looking statements. These forward-looking statements are based upon the Company's current expectations and projections about
future events and generally relate to plans, objectives, and expectations for the development of the Company's business, including the
timing and progress of preclinical studies, clinical trials, discovery programs and related milestones, the promise of the Company's portfolio
of therapies, and in particular its CAR-T therapies,
and the Company's refocus to a healthcare-oriented business. Although management believes that the plans and objectives reflected in or
suggested by these forward-looking statements are reasonable, all forward-looking statements involve risks and uncertainties, including
the possibility that the timeline for the Company's clinical trials might be impacted by the COVID-19 pandemic, and actual future results
may be materially different from the plans, objectives and expectations expressed in this press release. The Company has no obligation
to provide any updates to these forward-looking statements even if its expectations change. All forward-looking statements are expressly
qualified in their entirety by this cautionary statement. For further information on potential risks and uncertainties, and other important
factors, any of which could cause the Company's actual results to differ from those contained in the forward-looking statements, see the
section entitled "Risk Factors" in the Company's most recent Annual Report on Form 10-K and subsequent reports filed with the
Securities and Exchange Commission.
For more information, contact: